Who is eligible for clinical trial NCT03381274?

Participants must meet the protocol's inclusion criteria for Carcinoma, Non-Small-Cell Lung. The stated age range is 18 Years to 101 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT03381274 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-17

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (NCT03381274)

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: MedImmune LLC

🩺 Plain-English Summary (8th-Grade Level)

The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (16 items).

Location: Research Site — La Jolla, California

Age range: 18 Years to 101 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age ≥ 18
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Weight ≥ 35 kg
Diagnosed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFRm
For Arm A (Oleclumab + Osimertinib arms): must have received 1 prior line of therapy with an EGFR tyrosine kinase inhibitor (TKI) and confirmed T790M negative
For Arm B (Oleclumab + AZD4635 arms): must have received at least 2 but not more than 4 prior lines of therapy.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Receipt of an EGFR TKI within 14 days of the first dose of study treatment
Receipt of any conventional or investigational anticancer therapy not otherwise specified within 21 days of the planned first dose
Prior receipt of any investigational immunotherapy. Participants may have received agents that have local health authority approval for the disease indication
Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.
Participants with a history of venous thrombosis within the past 3 months
Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 6 months
Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment
Other invasive malignancy within 2 years
Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
Current or prior use of immunosuppressive medication within 14 days prior to the first dose Additional Exclusion Criteria for Arm A
Concurrent treatment (or inability to stop therapy) with medications or herbal supplements known to be potent inducers of cytochrome P (CYP) 3A4

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗